Patients treated with intravitreal injections of anti-high temperature requirement A1, a novel serine protease inhibitor, for the treatment of geographic atrophy experienced no serious study drug-related ocular or systemic adverse events.
“Single ascending dosages, as well as multiple dosages of 20 mg intravitreal anti-HtrA1, were well tolerated in patients. There were no dose-limiting toxicities observed at any level. There were no study drug-related ocular or systemic adverse events or serious adverse events observed,” Dante Pieramici, MD, said at the virtual Association for
Uncategorized